Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study

Autor: K. P. de Jong, Rob L. H. Jansen, C. Bisschop, Klaas Havenga, T. Wiggers, T. H. van Dijk, Geke A. P. Hospers, Hans Gelderblom, Harm J. T. Rutten, Jannet C. Beukema, C.J.H. van de Velde
Přispěvatelé: Radiotherapie, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: CAPHRI other, Surgery, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON), Groningen Institute for Organ Transplantation (GIOT), ​Robotics and image-guided minimally-invasive surgery (ROBOTICS)
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Male
Lung Neoplasms
Time Factors
PROGNOSIS
Organoplatinum Compounds
Colorectal cancer
SURGERY
medicine.medical_treatment
030230 surgery
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Neoadjuvant therapy
OUTCOMES
Liver Neoplasms
Radiotherapy Dosage
Middle Aged
CHEMOTHERAPY
Neoadjuvant Therapy
Bevacizumab
Oxaliplatin
Survival Rate
Oncology
030220 oncology & carcinogenesis
SYNCHRONOUS UNRESECTABLE METASTASES
Female
Radiology
medicine.drug
Adult
medicine.medical_specialty
RESECTION
Adenocarcinoma
Disease-Free Survival
PALLIATIVE RADIOTHERAPY
CHEMORADIOTHERAPY
Capecitabine
03 medical and health sciences
medicine
MANAGEMENT
Humans
Survival rate
Aged
Neoplasm Staging
Gastrointestinal Oncology
business.industry
Rectal Neoplasms
Chemoradiotherapy
Adjuvant
medicine.disease
Surgery
Radiation therapy
COLORECTAL LIVER METASTASES
business
Chemoradiotherapy
Zdroj: Annals of Surgical Oncology, 24(9), 2632-2638
Annals of Surgical Oncology
Annals of Surgical Oncology, 24(9), 2632-2638. Springer, Cham
Annals of Surgical Oncology, 24(9), 2632-2638. SPRINGER
ISSN: 1068-9265
Popis: Background. In a Dutch phase II trial conducted between 2006 and 2010, short-course radiotherapy followed by systemic therapy with capecitabine, oxaliplatin, and bevacizumab as neoadjuvant treatment and subsequent radical surgical treatment of primary tumor and metastatic sites was evaluated. In this study, we report the long-term results after a minimum follow-up of 6 years.Methods. Patients with histologically confirmed rectal adenocarcinoma with potentially resectable or ablatable metastases in liver or lungs were eligible. Follow-up data were collected for all patients enrolled in the trial. Overall and recurrence-free survival were calculated using the Kaplan-Meier method.Results. Follow-up data were available for all 50 patients. After a median follow-up time of 8.1 years (range 6.0-9.8), 16 patients (32.0%) were still alive and 14 (28%) were disease-free. The median overall survival was 3.8 years (range 0.5-9.4). From the 36 patients who received radical treatment, two (5.6%) had a local recurrence and 29 (80.6%) had a distant recurrence.Conclusions. Long-term survival can be achieved in patients with primary metastatic rectal cancer after neoadjuvant radio- and chemotherapy. Despite a high number of recurrences, 32% of patients were alive after a median follow-up time of 8.1 years.
Databáze: OpenAIRE
Externí odkaz: